NCT00920244

Brief Summary

The purpose of this study is to analyse transitions in cardiac rhythm and hemodynamic variables during resuscitation of patients with in-hospital cardiac arrest.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
285

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Aug 2009

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 12, 2009

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 15, 2009

Completed
2 months until next milestone

Study Start

First participant enrolled

August 1, 2009

Completed
5.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2015

Completed
Last Updated

September 5, 2018

Status Verified

August 1, 2018

Enrollment Period

5.7 years

First QC Date

June 12, 2009

Last Update Submit

August 31, 2018

Conditions

Heart ArrestDeath, Sudden, Cardiac

Keywords

ResuscitationCardiac arrestState-transitionsMarkov

Outcome Measures

Primary Outcomes (1)

  • Survival to discharge

    1 year

Secondary Outcomes (1)

  • Short-term survival

    minutes-days

Interventions

Cardiopulmonary resuscitation (CPR)PROCEDURE

CPR is performed according to international and national guidelines on all patients.

Also known as: CPR
EpinephrineDRUG

According to guidelines epinephrine 1 mg i.v. is administered every 3 minutes during cardiopulmonary resuscitation.

Also known as: Adrenaline
AtropineDRUG

According to CPR guidelines atropine 3 mg i.v. is administered if asystole og PEA with frequency \< 60 beat/min.

AmiodaroneDRUG

According to guidelines amiodarone 300 mg i.v. is administered if recurrent ventricular fibrillation/tachycardia (VF/VT) during CPR.

Also known as: Cordarone
External defibrillatorDEVICE

According to CPR guidelines patients with shockable rhythms may receive DC shocks. The defibrillator also stores physiological information regarding cardiac rhythm, pulse-oximetry, and end-tidal carbon dioxide (CO2) from endotracheal tube.

Also known as: Defibrillator

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with in-hospital cardiac arrest at St.Olavs Hospital (Trondheim, Norway) during the study period.

You may qualify if:

  • Patients with in-hospital cardiac arrest who are resuscitated

You may not qualify if:

  • Younger than 18 years old

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

St.Olavs Hospital, Department of Anesthesia

Trondheim, 7014, Norway

Location

Related Publications (2)

  • Skjeflo GW, Nordseth T, Loennechen JP, Bergum D, Skogvoll E. ECG changes during resuscitation of patients with initial pulseless electrical activity are associated with return of spontaneous circulation. Resuscitation. 2018 Jun;127:31-36. doi: 10.1016/j.resuscitation.2018.03.039. Epub 2018 Apr 3.

    PMID: 29621571RESULT

  • Nordseth T, Bergum D, Edelson DP, Olasveengen TM, Eftestol T, Wiseth R, Abella BS, Skogvoll E. Clinical state transitions during advanced life support (ALS) in in-hospital cardiac arrest. Resuscitation. 2013 Sep;84(9):1238-44. doi: 10.1016/j.resuscitation.2013.04.010. Epub 2013 Apr 19.

    PMID: 23603153DERIVED

MeSH Terms

Conditions

Heart ArrestDeath, Sudden, Cardiac

Interventions

Cardiopulmonary ResuscitationEpinephrineAtropineAmiodaroneDefibrillators

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesDeath, SuddenDeathPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

ResuscitationEmergency TreatmentTherapeuticsEthanolaminesAmino AlcoholsAlcoholsOrganic ChemicalsAminesBiogenic MonoaminesBiogenic AminesCatecholaminesCatecholsPhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsAtropine DerivativesTropanesAzabicyclo CompoundsAza CompoundsBelladonna AlkaloidsSolanaceous AlkaloidsAlkaloidsHeterocyclic CompoundsBridged Bicyclo Compounds, HeterocyclicHeterocyclic Compounds, Bridged-RingBenzofuransHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingElectrodesElectrical Equipment and SuppliesEquipment and Supplies

Study Officials

  • Eirik Skogvoll, MD, PhD

    St. Olavs Hospital

    STUDY CHAIR

  • Trond Nordseth, MD

    St. Olavs Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 12, 2009

First Posted

June 15, 2009

Study Start

August 1, 2009

Primary Completion

April 1, 2015

Study Completion

April 1, 2015

Last Updated

September 5, 2018

Record last verified: 2018-08

Locations

NO(1)